Breast Imaging Market to Reach USD 11.22 Billion by 2035 at 8.2% CAGR as AI-Driven Tomosynthesis Adoption Accelerates Early Cancer Detection

The global breast imaging market size was USD 5.10 Billion in 2025 and is expected to register a revenue CAGR of 8.2% during the forecast period. Breast imaging encompasses the systems and software used to screen for and diagnose breast cancer, including full-field digital mammography, digital breast tomosynthesis, breast ultrasound, breast magnetic resonance imaging, and the artificial intelligence tools that support image interpretation. Breast cancer is the most common cancer in women worldwide, with approximately 2.3 million new cases diagnosed each year according to the International Agency for Research on Cancer, and because early detection through imaging improves survival outcomes, national screening programmes sustain large and consistent demand for breast imaging equipment and software across all major markets.

The transition from two-dimensional digital mammography to three-dimensional digital breast tomosynthesis, which reduces recall rates and improves cancer detection, is driving capital replacement of the installed base of mammography systems across hospitals and screening centres. Adoption of artificial intelligence software to assist radiologists in detecting cancers and prioritising worklists, as well as the expansion of supplemental imaging such as breast ultrasound and contrast-enhanced techniques for women with dense breast tissue, broaden the imaging workflow and extend the value of breast imaging platforms beyond conventional mammography. For instance, in fiscal year 2024, Hologic, Inc., United States, which is a global leader in breast health technology, reported Breast Health segment revenue of USD 1,522.9 Million and agreed to acquire Endomagnetics Ltd for approximately USD 310 Million to expand its interventional breast cancer surgery portfolio while continuing to ship three-dimensional mammography gantries. These are some of the key factors driving revenue growth of the market.

However, digital breast tomosynthesis units and breast magnetic resonance imaging scanners carry high capital costs, and constrained hospital budgets combined with long equipment replacement cycles slow the rate of system upgrades even where clinical demand for improved imaging exists. Reimbursement for advanced modalities such as tomosynthesis and supplemental imaging varies by country and payer, affecting adoption speed, as well as shortages of radiologists and mammography technologists that limit screening throughput in many regions. Uneven access to organised screening across low and middle-income countries further constrains the addressable market. These factors substantially limit breast imaging market growth over the forecast period.

Request Your Free Sample Report: https://www.emergenresearch.com/request-free-sample/1888

SEGMENT HIGHLIGHTS

Based on technology, the global breast imaging market is segmented into ionising imaging and non-ionising imaging. The ionising imaging segment holds the largest revenue share in the market. This segment covers full-field digital mammography, digital breast tomosynthesis, and molecular breast imaging, and it dominates because mammography and tomosynthesis are the established primary screening tools globally, supported by the largest installed equipment base and the highest per-unit capital value, led by Hologic's three-dimensional mammography platform. The non-ionising imaging segment, which includes breast ultrasound and breast magnetic resonance imaging, is expected to register a rapid revenue growth rate in the global market over the forecast period, as supplemental screening for women with dense breasts expands and clinical indications for breast MRI broaden.

Based on modality, the global breast imaging market is segmented into full-field digital mammography, digital breast tomosynthesis, breast ultrasound, breast MRI, and others. The digital breast tomosynthesis segment holds a significantly large revenue share because three-dimensional tomosynthesis has become the preferred primary screening technology in many markets, with its ability to improve detection compared to two-dimensional mammography making it the largest driver of capital spending in the breast imaging category. The breast MRI segment is expected to register a rapid revenue growth rate in the global market over the forecast period, as its use for high-risk screening, diagnostic problem-solving, and pre-surgical disease extent assessment continues to expand, supported by the high unit value of MRI systems.

Request a Discount on This Report: https://www.emergenresearch.com/request-for-discount/1888

REGIONAL HIGHLIGHTS

Based on regional analysis, the breast imaging market in North America accounted for largest revenue share in 2025. The United States is the dominant country market, supported by an organised breast cancer screening infrastructure, high adoption of digital breast tomosynthesis, state-level dense-breast notification and supplemental imaging legislation, as well as favourable reimbursement for advanced modalities. The U.S. Food and Drug Administration's ongoing updates to mammography quality standards have reinforced tomosynthesis as the reference screening technology. Hologic, the global market leader in breast health with Breast Health segment revenue of USD 1,522.9 Million in fiscal 2024, is headquartered in the United States and maintains the largest installed base of tomosynthesis systems in the region. The U.S.-Iran conflict, which escalated through late 2025 and into Q1 and Q2 2026, contributed to elevated semiconductor and precision component costs that increased the manufacturing and procurement costs of advanced imaging systems across the region.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom operate well-organised national breast screening programmes that sustain consistent replacement and upgrade demand for mammography and tomosynthesis systems. Siemens Healthineers AG, headquartered in Germany, is a key regional supplier with a broad breast imaging portfolio covering mammography, ultrasound, and MRI, as well as an expanding artificial intelligence software offering integrated with its imaging platforms. The escalation of the U.S.-Iran conflict through Q1 and Q2 2026 raised energy prices and disrupted certain electronic component supply chains across Europe, increasing the cost base for imaging equipment procurement and installation.

The market in Asia Pacific is expected to register the fastest revenue growth rate over the forecast period. China, Japan, and India are the primary markets, where rising breast cancer incidence, expanding organised screening programmes, increasing public healthcare investment, and growing access to diagnostic imaging facilities are driving demand for mammography, tomosynthesis, and ultrasound systems. Fujifilm Holdings Corporation and Canon Medical Systems Corporation, both headquartered in Japan, supply mammography and tomosynthesis systems across the region and are positioned to benefit from accelerating screening expansion. Disruptions to semiconductor and precision component supply chains arising from the U.S.-Iran conflict and its spillover effects through Q1 and Q2 2026 introduced procurement delays for imaging equipment importers in the region, which affected delivery timelines for capital systems.

Read the Full Report Description: https://www.emergenresearch.com/industry-report/breast-imaging-market

MAJOR COMPANIES IN THE REPORT INCLUDE:

Hologic, Inc. (United States)
GE HealthCare Technologies Inc. (United States)
Siemens Healthineers AG (Germany)
Fujifilm Holdings Corporation (Japan)
Canon Medical Systems Corporation (Japan)
Koninklijke Philips N.V. (Netherlands)
Carestream Health, Inc. (United States)
iCAD, Inc. (United States)
ScreenPoint Medical B.V. (Netherlands)
Densitas Inc. (Canada)
Delphinus Medical Technologies, Inc. (United States)
Endomagnetics Ltd (Hologic) (United Kingdom)

Contact
Eric Lee
Corporate Sales Specialist, USA
Emergen Research | Web: www.emergenresearch.com
Direct Line: +12092086299
E-mail: sales@emergenresearch.com

About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries including Healthcare, Technology, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trend existing in the market.

This release was published on openPR.